These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16432637)

  • 1. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.
    Mushiroda T; Ohnishi Y; Saito S; Takahashi A; Kikuchi Y; Saito S; Shimomura H; Wanibuchi Y; Suzuki T; Kamatani N; Nakamura Y
    J Hum Genet; 2006; 51(3):249-253. PubMed ID: 16432637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
    Miyagata Y; Nakai K; Sugiyama Y
    Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
    Zhu Y; Shennan M; Reynolds KK; Johnson NA; Herrnberger MR; Valdes R; Linder MW
    Clin Chem; 2007 Jul; 53(7):1199-205. PubMed ID: 17510308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
    Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
    BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
    Veenstra DL; You JH; Rieder MJ; Farin FM; Wilkerson HW; Blough DK; Cheng G; Rettie AE
    Pharmacogenet Genomics; 2005 Oct; 15(10):687-91. PubMed ID: 16141794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.
    Shrif NE; Won HH; Lee ST; Park JH; Kim KK; Kim MJ; Kim S; Lee SY; Ki CS; Osman IM; Rhman EA; Ali IA; Idris MN; Kim JW
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1119-30. PubMed ID: 21590310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation.
    Yang J; Huang C; Shen Z; Miao L
    Int J Clin Pharmacol Ther; 2011 Jan; 49(1):23-9. PubMed ID: 21176721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
    Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
    Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
    Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
    Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.